VivoSeq
Dermatology

Dermatitis, Atopic

8

Pipeline Programs↗

6

Active Trials↗

5

Companies Involved↗

Dermatitis, Atopic is an early-stage landscape with 8 programs across 5 companies. The most active players are Johnson & Johnson, Eli Lilly, Sanofi. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3Sanofi logo

Sanofi

5 programs

Phase 3S

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 50% of 10 pipeline programs.

Analysis

Trial Status

9

clinical trials

Recruiting3 · 33%
Active, not recruiting2 · 22%
Completed2 · 22%
Terminated1 · 11%
Enrolling by invitation1 · 11%

Clinical Trials

Trial Activity

9 trials

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT07230860·180 enrolled
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment
Recruiting·Sanofi logoSanofi·Phase 3·NCT06241118·636 enrolled
A Prospective Observational Study of Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Receiving Dupilumab
Recruiting·Sanofi logoSanofi·N/A·NCT06192563·150 enrolled
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 52-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Active, not recruiting·Sanofi logoSanofi·Phase 3·NCT06407934·1,541 enrolled
The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib
Active, not recruiting·Pfizer logoPfizer·N/A·NCT06353087·41 enrolled
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.
Enrolling by invitation·Sanofi logoSanofi·Preclinical·NCT05492578·1,663 enrolled
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable
Completed·Sanofi logoSanofi·N/A·NCT03849716·266 enrolled
A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetic and Efficacy of Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) in Chinese Children and Adolescents (6 Years Old ≤ Age <18 Years Old) With Moderate to Severe Atopic Dermatitis
Completed·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Preclinical·NCT06324812·128 enrolled
95475939ADM2001: 95475939ADM2001 Ph IIB Trial (N=210)
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT06881251·256 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)